Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy:... by Schoenfeld, Jonathan D, MD, Giobbie-Hurder, Anita, MS, Ranasinghe, Srinika, PhD, Kao, Katrina Z, BA, Lako, Ana, PhD, Tsuji, Junko, PhD, Liu, Yang, PhD, Brennick, Ryan C, BS, Gentzler, Ryan D, MD, Lee, Carrie, MD, Hubbard, Joleen, MD, Arnold, Susanne M, Prof, Abbruzzese, James L, Prof, Jabbour, Salma K, Prof, Uboha, Nataliya V, MD, Stephans, Kevin L, MD, Johnson, Jennifer M, MD, Park, Haeseong, MD, Villaruz, Liza C, MD, Sharon, Elad, MD, Streicher, Howard, MD, Ahmed, Mansoor M, PhD, Lyon, Hayley, BA, Cibuskis, Carrie, BS, Lennon, Niall, PhD, Jhaveri, Aashna, MS, Yang, Lin, MS, Altreuter, Jennifer, MD, Gunasti, Lauren, BA, Weirather, Jason L, PhD, Mak, Raymond H, MD, Awad, Mark M, MD, Rodig, Scott J, MD, Chen, Helen X, MD, Wu, Catherine J, Prof, Monjazeb, Arta M, Prof, Hodi, F Stephen, Prof

Get full text